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Porto, Lisbon, PortugalBackground and Aims: Postprocedural bleeding (PPB) is the most common adverse event associated with
endoscopic resection. Several studies have tried to identify risk factors for PPB after gastric EMR and endoscopic
submucosal dissection (ESD), with controversial results. This systematic review and meta-analysis aimed to iden-
tify signiﬁcant risk factors for PPB after gastric EMR and ESD.
Methods: Three online databases were searched. Pooled odds ratio (OR) was computed for each risk factor using
a random-effects model, and heterogeneity was assessed by Cochran’s Q test and I2.
Results: Seventy-four articles were included. Pooled PPB rate was 5.1% (95% conﬁdence interval, 4.5%-5.7%),
which did not vary according to different study designs. Male sex (OR, 1.25), cardiopathy (OR, 1.54), antithrom-
botic drugs (OR, 1.63), cirrhosis (OR, 1.76), chronic kidney disease (OR, 3.38), tumor size > 20 mm (OR, 2.70),
resected specimen size > 30 mm (OR, 2.85), localization in the lesser curvature (OR, 1.74), ﬂat/depressed
morphology (OR, 1.43), carcinoma histology (OR, 1.46), and ulceration (OR, 1.64) were identiﬁed as signiﬁcant
risk factors for PPB, whereas age, hypertension, submucosal invasion, ﬁbrosis, and localization (upper, middle, or
lower third) were not. Procedure duration > 60 minutes (OR, 2.05) and the use of histamine-2 receptor antago-
nists instead of proton pump inhibitors (OR, 2.13) were the procedural factors associated with PPB, whereas en-
doscopist experience and preprocedural proton pump inhibitors were not. Second-look endoscopy was not
associated with decreased PPB (OR, 1.34; 95% conﬁdence interval, .85-2.12).
Conclusions: Risk factors for PPB were identiﬁed that can help to guide management after gastric ESD, namely
adjusting further management. Second-look endoscopy is not associated with decreased PPB. (Gastrointest
Endosc 2016;84:572-86.)Endoscopic submucosal dissection (ESD) and EMR are
well-established treatments for early gastric neoplasms.1
Bleeding is the most frequent adverse event associated
with ESD and EMR, occurring in 7.1% to 9.4% and 7.1%
to 8.6% of the procedures, respectively.2-4 Speciﬁcally,
postprocedural bleeding (PPB) is reported to occur in
4.53% after ESD and 3.97% after EMR.2
Both patient and lesion characteristics, as well as medi-
cations and procedural technical features, may inﬂuencens: AT, antithrombotic therapy; CI, confidence interval; ESD,
submucosal dissection; H2RA, histamine-2 receptor antago-
ds ratio; PPB, postprocedural bleeding; PPI, proton pump in-
, randomized controlled trial; SLE, second-look endoscopy.
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ROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016the risk of bleeding. Several studies have addressed this
issue over time, aiming at identifying risk factors for PPB.
However, some controversy exists, and the signiﬁcant
risk factors for post-EMR/ESD bleeding are yet to be iden-
tiﬁed. The identiﬁcation of these risk factors is of para-
mount importance to estimate bleeding risk and to
stratify patients, namely to guide management after ESD/
EMR. Therefore, we aimed at identifying the risk factors
for PPB after EMR and ESD for early gastric neoplasms.METHODS
Study search and selection
Studies were identiﬁed through scanning of 3 electronic
databases (MEDLINE through PubMed, Scopus, and ISI
Web of Knowledge), with the last search performed on
July 15, 2015. The search query for PubMed was ([gastric
OR stomach] AND [“endoscopic submucosal dissection”
OR “endoscopic mucosal resection”]) AND (bleeding ORwww.giejournal.org
Libânio et al Risk factors for bleeding after gastric ESDhemorrhage). Queries for other databases were adapted
from this query. Additional studies were identiﬁed by
checking the list of references of all included studies and
reviews on the topic.
Two independent investigators (D.L., M.N.C.) screened
titles and abstracts to exclude irrelevant studies. The full
text of relevant studies was then analyzed by these same
authors according to the criteria below. Disagreements
were solved by consensus with the intervention of a third
reviewer (P.P.N.) when required. This phase was per-
formed with Covidence online platform (www.covidence.
org).
Abstracts and fully published studies were considered
for inclusion with no date or language restrictions. Inclu-
sion criteria were (1) retrospective or prospective,
case-control or cohort studies and clinical trials (including
randomized controlled trials [RCTs]); (2) studies evalu-
ating patients submitted to EMR or ESD to treat gastric su-
perﬁcial neoplasms (dysplastic lesions or early gastric
cancers); (3) studies with PPB rates reported separately
from intraprocedural bleeding; and (4) studies where risk
factors for PPB were analyzed. Articles were excluded if
(1) PPB rates were not clearly reported; (2) fewer than
20 patients were included; (3) they were feasibility studies
of innovative techniques/devices without control group;
(4) they were comments, reviews, letters, or surveys; (5)
they were case reports; or (6) they were animal studies.
Quality evaluation and data extraction
Data extraction and quality assessment were performed
by D.L. using prespeciﬁed forms that were reﬁned after pi-
loting in 10 studies. Another reviewer (M.N.C.) indepen-
dently checked the extracted data, and disagreements
were solved by consensus. Data extraction forms included
(1) author, (2) publication year, (3) setting, (4) study
period, (5) study design, (6) randomization methods if
applicable, (7) allocation concealment, (8) blinding, (9)
type of endoscopic resection (EMR/ESD), (10) number of
participants, (11) deﬁnition of PPB, (12) frequency of
PPB (total and for each risk factor), (13) antacids (route,
dosage, duration of therapy), (14) antithrombotic manage-
ment, (15) operator (single/multiple, experienced/nonex-
perienced), and (16) second-look endoscopy (SLE). In
the data extraction form, crude data and results of statisti-
cal analysis were recorded for each risk factor. Quality eval-
uation was performed using the Cochrane risk of bias tool
for RCTs5 and the Newcastle-Ottawa scale for observational
studies.6 Also, the quality of reporting of acid inhibition
strategy and antithrombotic management was assessed.
Data synthesis and statistical analysis
Odds ratios (ORs) and 95% conﬁdence intervals (CIs)
for each categoric risk factor and the mean or median for
continuous data was registered (or calculated whenever
possible). Studies providing data allowing the calculation
of ORs were then included in a meta-analysis, performedwww.giejournal.orgby computing pooled ORs (for categoric variables) and
mean differences (for continuous variables) using a
random-effects model. Pooled PPB prevalence was calcu-
lated with a random-effects model with OpenMetaAnalyst.7
Meta-analysis was performed using RevMan 5.3.8 Heteroge-
neity was evaluated with the Cochran Q test and I2. Signif-
icant heterogeneity was deﬁned as I2 > 40% and P < .05.
For continuous outcomes, median and interquartile
range/range were transformed into mean and standard de-
viation through the methods proposed by the Cochrane
collaboration and Hozo et al.9 Sensitivity analysis was
planned, excluding these studies and whenever signiﬁcant
heterogeneity was found. Subgroup analysis was planned
according to study design, time of bleeding (early or de-
layed), and antithrombotic management. This study was
conducted in accordance with the PRISMA recommenda-
tions for reporting systematic reviews and meta-analysis.10RESULTS
Characteristics of included studies and quality
evaluation
In total, 1043 studies were identiﬁed (1038 through
database search and 5 through manual searching), and
74 references (71 studies) were ﬁnally included in this sys-
tematic review (Fig. 1). A summary of the included studies
and quality evaluation (15 RCTs, 3 prospective trials, 5 pro-
spective cohort studies, and 48 retrospective cohort and
case-control studies) is shown in Table 1. Seventy-three
percent of RCTs were judged to have low risk of bias,
whereas observational studies had a median and mean
Newcastle-Ottawa score of 7 and 7.5, respectively. Almost
all studies reported that proton pump inhibitors (PPI) or
histamine-2 receptor antagonists (H2RAs) were adminis-
tered in the periprocedural period, although route,
dosage, frequency of administration, and duration of treat-
ment were not accurately reported in 42% of the studies.
Moreover, the management of antithrombotics was not
clearly reported in 24 studies (32%).
PPB deﬁnition and rate
The most common deﬁnition of PPB was clinical evi-
dence of bleeding (hematemesis/melena) or hemoglobin
drop  2 g/dL requiring endoscopic hemostasis. Deﬁni-
tions of early and delayed bleeding were heterogeneous
among studies, with some studies deﬁning early bleeding
as those occurring in the ﬁrst 24 hours, whereas others
considered early bleeding those that occurred in the ﬁrst
48 hours or in the ﬁrst 5 days after ESD.
PPB rates ranged from .6%11 to 26.9%,12 and the pooled
PPB rate was 5.1% (95% CI, 4.5%-5.7%), with signiﬁcant
heterogeneity across studies (I2 Z 84.46, P < .001). How-
ever, PPB rates were not signiﬁcantly different according to
study design (5.9% in RCTs, 6.1% in prospective studies,
and 4.9% in retrospective studies; I2 > 80%).Volume 84, No. 4 : 2016 GASTROINTESTINAL ENDOSCOPY 573
 1043 references identified
 665 titles/abstracts screened
 284 articles assessed for full-text eligibility
 74 articles included (71 studies)
 -  70 full-published papers
 -   4 abstracts
62 studies included in meta-analysis
378 duplicates removed
381 articles excluded
(irrelevant)
210 articles excluded
- 45 post-procedural bleeding not clearly defined
- 41 review/comment/survey/letter to editor
- 40 post-procedural bleeding not accurately reported
- 27 risk factors for bleeding not searched
- 25 feasibility study without control group
- 16 less than 20 patients
- 9 animal study or not gastric EMR/ESD or case report
- 7 submucosal or non-neoplastic lesion included
Figure 1. Flowchart of included studies.
Risk factors for bleeding after gastric ESD Libânio et alThe time of bleeding was determined in 28 studies. Def-
initions of early and delayed bleeding were also heteroge-
neous across studies. Most bleeding episodes (213/374;
56.9%) occurred more than 24 hours after ESD. Among
the 4 studies classifying early PPB as bleeding < 48 hours
after ESD, 92 of 135 PPB events (68.2%) occurred in this
time period. As stated below, among those studies report-
ing delayed bleeding (>48 hours after ESD) only, upper
localization was associated with a higher bleeding risk.Risk factors for PPB
All included studies explored risk factors for PPB after
ESD, whereas risk factors for PPB after EMR were evaluated
in 3 studies. Most studies (54%) evaluated multiple risk fac-
tors (case-control design), whereas 46% focused on single
risk factors (eg, age, size, premedication with PPIs). Signif-
icant risk factors found in the meta-analysis are summa-
rized in Figure 2, and the effect estimates for each risk
factor are shown in Tables 2, 3, and 4.
Patient factors. Age was not identiﬁed as a risk
factor in most studies,13-33 with only 1 study reporting
that younger patients may be at higher risk for PPB.34
Furthermore, 10 studies found no signiﬁcant differences
in elderly patients,19,25,30,35-41 although 1 study identiﬁed
age > 80 years as an independent risk factor for
PPB.42 PPB rates were similar between genders in most
studies,13-18,20-23,25-34,36,39,42-44 with only 1 study reporting
an association male sex associated with PPB.24
Arterial hypertension was not identiﬁed as a risk
factor in most studies,13-15,17,18,20-24,28-31,33,42,43,45 although
2 studies reported signiﬁcantly higher PPB rates in
hypertensive patients.16,36 However, the adjusted OR was
.67 in the latter study.36 Similarly, diabetes mellitus574 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016was not identiﬁed as a signiﬁcant risk factor in any
study.13-18,20-24,28-31,33,34,36,42,44,45
Cardiopathy (ischemic heart disease in most
studies),10,13,17,20,23,28,29,31,34,36,42,44,45 cerebrovascular dis-
ease,15,21-23,28,36,42,45 and cirrhosis14,17,18,22,24,26,28,29,34,36,43,45
were not identiﬁed as risk factors for PPB in most studies.
Chronic kidney disease was not identiﬁed as a risk factor
in some studies despite a trend to higher
bleeding.14,17,22,28,30,34,42 However, 3 studies found signiﬁ-
cantly increased PPB rates in patients with chronic kidney
disease45 and undergoing dialysis.18,46
Comorbidities28,45 and American Society of Anesthesiol-
ogists Physical Status Classiﬁcation System status47 were
not identiﬁed to be associated with PPB, although 1 study
found increased PPB risk in patients with signiﬁcant co-
morbidities.25 Other clinical factors were analyzed in a
few studies. Helicobacter pylori infection,13,14,22 body
mass index,22,29,36 hyperlipidemia,24,29,31,34,42 hyperurice-
mia,36 pulmonary disease,34 history of peptic ulcer,31
hemoglobin level,22 prothrombin, and activated partial
thromboplastin time22,25 were not found to be associated
with PPB. Thrombocytopenia was associated with PPB in
1 study,43 although 2 studies did not ﬁnd differences in
PPB rates.16,22
Finally, previous gastric surgery (ESD in gastric remnant
or gastric tube) was not associated with increased
PPB.22,48,49 However, 1 study found a higher PPB rate
when the anastomotic site was involved.48
After meta-analysis, male sex, cardiopathy, cirrhosis, and
chronic kidney disease were signiﬁcantly associated with
PPB. Among patients with chronic kidney disease, dialysis
was associated with an increased PPB risk (Table 2). Again,
age, hypertension, diabetes mellitus, and cerebrovascular
disease were not found to inﬂuence PPB.www.giejournal.org
TABLE 1. General characteristics of included studies
Country Period
Resection
method, n
Overall
PPB (%)
Risk factors
evaluated Quality*
Included in
meta-analysisy
RCTs
Ono S, 200911 Japan 04-07 ESD, 155 .6 Single (pre-PPI) Low risk Yes
Lee BI, 201169 Korea 08-09 ESD, 52 1.9 Single (closure) Unclear risk No
Watanabe Y, 200679 Japan 02-03 ESD, 98 3.1 Single (pre-PPI) High risk Yes
Imaeda H, 201180 Japan 08-10 ESD, 123 4.1 Single (PPI vs H2RA) Low risk Yes
Kim S, 201474 Korea 11-12 ESD, 120 4.2 Single (early diet) Low risk No
Mochizuki S, 201584 Japan 12-13 ESD, 262 4.6 Multiple Low risk Yes
Kim JS, 201422 Korea 12-13 ESD, 446 5.2 Multiple Low risk Yes
Tomita T, 201232 Japan 08-10 ESD, 156 5.7 Multiple Low risk Yes
Baeg MK, 201477 Korea NR ESD, 98 6.1 Single (pre-PPI) Unclear risk Yes
Uedo N, 200681,z Japan 05 ESD, 105 6.7 Single (PPI vs H2RA) Unclear risk Yes
Ahn JY, 201562 Korea 08-09 ESD, 79 7.6 Single (ecabet sodium) Low risk Yes
Jeong HK, 200760 Korea 05-06 ESD, 164 7.9 Multiple Low risk Yes
Choi CW, 201514 Korea 12-13 ESD, 273 8.4 Multiple Low risk Yes
Uedo N, 200759 Japan 05-06 ESD, 143 10.5 Multiple Low risk Yes
Ryu HY, 201361 Korea 11-12 ESD, 155 13.5 Multiple Low risk Yes
Prospective studies
Hikichi T, 201478 Japan 07-08 ESD, 55 1.8 Single (pre-PPI) 8 Yes
Lim SM, 201383 Korea 08-11 ESD, 1461 4.4 Single (fatigue) 9 No
Park CH, 201530 Korea 11-12 ESD, 459 5.4 Multiple 9 Yes
Kikuchi D, 201373 Japan 08-10 ESD, 89 5.6 Single (EUS findings) 7 No
Na S, 201528 Korea 11-12 ESD, 706 5.8 Multiple 7 Yes
Nishide N, 201248 Japan 02-09 ESD, 1541 10.6 Single (remnant) 7 Yes
Tsuji Y, 201572 Japan 13-14 ESD, 86 13.9 Single (PGA sheets) 9 No
Ono S, 201512 Japan 12-14 ESD, 26 26.9 Multiple 8 Yes
Retrospective studies
Ahn SY, 201475 Korea 07-08 ESD, 105 .9 Single (early discharge) 7 No
Ahn JY, 201164 Korea 94-09 ESD, 833; EMR, 537 1.3/1.5 Single (indication) 7 Yes
Oda I, 201282 Japan 99-08 ESD, 464 1.5 Single (experience) 6 Yes
Shimura T, 200755 Japan 99-05 ESD, 59; EMR, 48 1.7/4.2 Multiple 7 Yes
Lee JY, 201049 Korea 04-08 ESD, 43 2.3 Single (remnant) 7 Yes
Isomoto H, 201019 Japan 01-07 ESD, 713 2.5 Single (age) 7 Yes
Yamaguchi N, 200963 Japan 01-07 ESD, 713 2.5 Single (indication) 7 Yes
Kim ER, 201520 Korea 09-10 ESD, 550 2.5 Multiple 8 Yes
Higashiyama M, 201118 Japan 05-09 ESD, 924 3.0 Multiple 9 Yes
Akasaka T, 201176 Japan 03-08 ESD, 1188 3.1 Multiple 4 No
Mukai S, 201370 Japan 07-12 ESD, 234 3.4 Single (clipping) 7 No
Sugimoto T, 201239 Japan 02-08 ESD, 485 3.7 Multiple 9 Yes
Asakuma Y, 201157,z Japan 02-07 ESD, 386 3.9 Multiple 6 No
Goto O, 200968 Japan 04-07 ESD, 119 4.0 Snaring 8 No
Kim SE, 201323 Korea 06-11 ESD, 396 4.0 Multiple 7 Yes
Cho SJ, 201215 Korea 99-03 ESD, 514 4.1 Multiple 9 Yes
Kawai N, 200752,z and 201253 Japan 03-05 ESD, 552 4.2 Single (antithrombotics) 6 Yes
Okada K, 201129 Japan 05-08 ESD, 582 4.3 Multiple 9 Yes
(continued on the next page)
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TABLE 1. Continued
Country Period
Resection
method, n
Overall
PPB (%)
Risk factors
evaluated Quality*
Included in
meta-analysisy
Kim HH, 201221 Korea 08-10 ESD, 442 4.3 Multiple 7 Yes
Takeuchi T, 201354 Japan 02-12 ESD, 833 4.3 Multiple 7 Yes
Sanomura Y, 201450 Japan 05-12 ESD, 94 4.3 Single (antithrombotics) 7 Yes
Ebi M, 201416 Japan 05-12 ESD, 186 4.3 Multiple 9 Yes
Kosaka T, 201465 Japan 02-07 ESD, 438 4.3 Single (indication) 7 Yes
Man-i M, 201347 Japan 07-10 ESD, 527 4.4 Single (ASA) 7 Yes
Hirasaki S, 200756 Japan 02-06 ESD, 112 4.5 Single (size) 7 Yes
Kim BJ, 201045 Korea 03-06 ESD, 337 4.7 Single (comorbidity) 7 Yes
Matsumura T, 201426 Japan 05-14 ESD, 425 4.7 Multiple 7 Yes
Toyokawa T, 201242 Japan 03-10 ESD, 1123 5.0 Multiple 7 Yes
Takahashi F, 201434 Japan 04-13 ESD, 459 5.0 Multiple 7 Yes
Suzuki H, 201571 Japan 95-06 ESD, 1713 5.1 Single (experience) 7 Yes
Chinda D, 201535 Japan 04-09 ESD, 307 5.2 Single (age) 7 Yes
Yoshio T, 201340 Japan 03-11 ESD, 1250 5.3 Single (antithrombotics) 6 No
Koh R, 201324 Japan 00-10 ESD, 1166 5.3 Multiple 9 Yes
Jeong JY, 201267 Korea 06-11 ESD, 167 5.4 Single (fibrosis) 7 Yes
Choi CW, 201413 Korea 08-12 ESD, 616 5.6 Multiple 9 Yes
Onochi K, 201051,z Japan 03-09 ESD, 468 5.6 Single (antithrombotics) 6 Yes
Goto O, 201017 Japan 03-08 ESD, 454 5.7 Multiple 7 Yes
Takizawa T, 200831 Japan 00-04 ESD, 1083 5.8 Multiple 8 Yes
Tusji Y, 201033 Japan 07-09 ESD, 398 5.8 Multiple 9 Yes
Lim JH, 201225 Korea 05-10 ESD, 1591 5.9 Multiple 9 Yes
Zhang Y, 201441 China 10-13 ESD, 187 5.9 Single (age) 7 Yes
Nakamura M, 201243 Japan 06-11 ESD, 544 6.9 Multiple 9 Yes
Miyahara K, 201236
Mannen K, 201044
Japan 01-10 ESD, 1082 6.9 Multiple 9 Yes
Onozato Y, 200637 and 200838 Japan 02-06 ESD, 226 7.5 Multiple 7 Yes
Oka S, 200666 Japan 90-04 ESD, 195; EMR, 825 11.3/7.0 Single (ulceration) 6 No
Mukai S, 201227 Japan 07-10 ESD, 161 13 Multiple 9 Yes
Numata N, 201346 Japan 04-12 ESD, 79 13.9 Single (dialysis) 7 Yes
Chung I-K, 200958 Korea 06-07 ESD, 1000 15.6 Multiple 9 Yes
NR, Not reported; PGA, polyglycolic acid sheets; ASA, American Society of Anesthesiologists Physical Status Classification System; RCT, randomized controlled trial; PPB,
postprocedural bleeding; ESD, endoscopic submucosal dissection.
*Quality evaluation using Cochrane risk of bias table for randomized controlled trials and Newcastle-Ottawa scale for observational studies.
yRisk factors evaluated in only 1 study were not included in meta-analysis as well as studies not providing data, allowing calculation of odds ratio.
zAbstract.
Risk factors for bleeding after gastric ESD Libânio et alMedications. Seventeen studies32,39,48,49,55,57,58,63-
68,70,71,76,82 did not report whether patients with anti-
thrombotic therapy (AT) were included, and 9
studies11,59,60,62,73,74,77,79,81 excluded patients on AT
(pooled PPB rates, 5.0% and 5.4%). Seven
studies16,27,35,52,53,56,75 did not clearly report AT manage-
ment (pooled PPB, 3.6%), whereas this was adequately
reported in the remaining studies.
AT was not identiﬁed as a risk factor in 17 studies.13,14,16-
18,20-23,27-31,36,42,43 However, meta-analysis showed that PPB
was signiﬁcantly associated with AT use (Fig. 3). In sub-
group analysis PPB risk was not signiﬁcantly increased if576 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016AT were withheld 1 week before and after ESD, whereas
AT resumption immediately after ESD was signiﬁcantly
associated with PPB.
Regarding low-dose aspirin, a study found that PPB was
more frequent in continuous aspirin users than in those
who never used or discontinued aspirin therapy, with a
trend to later bleeding.15 On the other hand, 2 studies
found no signiﬁcant increase in PPB rates in patients sub-
mitted to ESD under low-dose aspirin despite a tendency
to higher bleeding.25,26,50 Other studies found that
PPB was associated with the use of anticoagulants51 and
double AT52,53 but not with antiplatelet monotherapy. Onwww.giejournal.org
Risk factors for post-ESD bleeding
Risk Factor
Chronic Kidney disease
 (13)
1 2 4 6
1.25
1.43
1.03
1.12
1.12
1.05
1.3
1.21
1.1
1.14
1.19
1.21
1.44
1.4
2.31 4.97
5.77
5.06
3.74
3.55
2.73
2.73
2.21
2.03
2.25
1.91
1.84
1.52
UCLLCLOR
1.46
1.54
1.63
1.64
1.74
1.76
2.05
2.13
2.7
2.85
3.38
1
Specimen > 30 mm (2)
Tumor > 20 mm (6)
H2RA (6)
ESD>60 min (3)
Cirrhosis (12)
Lesser curvature (9)
Ulceration (18)
Cardiopathy (15)
Antithrombotics (22)
Carcinoma (14)
Flat/depressed (17)
Male sex (25)
Figure 2. Signiﬁcant risk factors for post-procedural bleeding after gastric ESD. In the ﬁrst column, the numbers between parentheses refer to the num-
ber of studies used in the calculation of odds ratio. LCL, lower conﬁdence limit (95%); UCL, upper conﬁdence limit (95%).
Libânio et al Risk factors for bleeding after gastric ESDthe other hand, thienopyridines were associated with
higher PPB risk even with discontinuation for 5 to
8 days before and resumption at a median of 3 days after
ESD.12
Heparin replacement was not identiﬁed as a signiﬁcant
risk factor in 1 study,43 although an opposite result was
found in another study.40 Gastroprotective agents were
associated with lower PPB in patients undergoing AT in 1
study.54 Corticosteroid use was not identiﬁed as a risk fac-
tor for PPB.16,24,43
Lesion characteristics. Tumor size and resected
specimen size were evaluated as risk factors in several
studies. Lesion sizes > 10 mm55 and >20 mm43,56 were
not found to increase PPB in some studies, whereas lesion
sizes > 20 mm,20,22,39,57-59 >30 mm,39 and >40 mm58 were
found to be associated with higher PPB risk in others.
Regarding specimen size, the larger the ulcer, the higher
the risk, with an artiﬁcial ulcer > 30 mm,36 34 mm,60
>40 mm,23-26,30,61 and >50 mm36,43 identiﬁed as risk fac-www.giejournal.orgtors for PPB in diverse studies. When the studies evaluated
the mean sizes of tumors and resected specimens between
those with PPB and those without, the results were con-
ﬂicting, with some reporting signiﬁcant differences be-
tween tumor22,26,34,42 and specimen21,23,24,29,34,42 sizes
and others not ﬁnding signiﬁcant differences between
the 2 groups.13,14,16-18,20,27,28,31-33,51
In addition, results concerning whether tumor location
impacts PPB were controversial. Four studies reported
that tumors located in the lower third33,34,36,57 and in the
middle/lower third27,31,37,38 of the stomach had signiﬁ-
cantly higher bleeding rates, whereas the upper location
of the stomach was found to be a signiﬁcant risk factor
in other studies.30,58 However, several studies reported
no signiﬁcant differences in PPB according to tumor
location.14-18,20-29,32,39,42,43,51,55,61 Horizontal localization
(anterior or posterior wall; lesser or greater
curvature) was not found to inﬂuence PPB in individual
studies.15-17,20-24,27,29 Regarding the relationship betweenVolume 84, No. 4 : 2016 GASTROINTESTINAL ENDOSCOPY 577
TABLE 2. Demographic and clinical risk factors
Risk factor (number of studies) PPB/total (%) ORPPB* I
2
Age (20) –.46 y (–.49, 1.42) 16%
>75 y 22/525 (4.2%)
40/908 (4.4%)
.99 (.58-1.69) 0%
Male (25) 583/11,103 (5.2%)
155/3865 (4.0%)
1.25 (1.03-1.52) 4%
Hypertension (20) 193/4108 (4.7%)
315/7253 (4.3%)
1.06 (.86-1.30) 13%
Diabetes mellitus (20) 78/1644 (4.7%)
473/10,263 (4.6%)
1.06 (.83-1.36) 0%
Cardiopathy (15) 63/951 (6.6%)
399/8771 (4.5%)
1.54 (1.05-2.25) 33%
Cerebrovascular disease (8) 7/221 (3.2%)
223/4798 (4.6%)
1.67 (.42-6.61) 69%
Cirrhosis (12) 23/287 (8.0%)
362/6895 (5.2%)
1.76 (1.14-2.73) 0%
Chronic kidney disease (13) 38/275 (13.8%)
359/7439 (4.8%)
3.38 (2.31-4.97) 0%
Chronic kidney disease (7) 20/171 vs 177/3553 2.97 (1.76-5.01) 0%
Hemodialysis (6) 18/104 vs 182/3886 3.94 (2.24-6.94) 0%
Significant comorbidities (4) 58/899 (6.4%)
103/2151 (4.8%)
1.49 (.81-2.75) 60%
Helicobacter pylori (4) 35/1022 (3.4%)
29/676 (4.3%)
.87 (.50-1.50) 0%
Hyperlipidemia (5) 26/489 (5.3%)
206/3809 (5.4%)
1.07 (.70-1.63) 0%
Previous gastric surgery (4) 6/92 (6.5%)
232/3056 (7.6%)
.91 (.41-2.01) 0%
Values in bold indicate significant risk factors.
PPB, Post-procedural bleeding; OR, odds ratio.
*Mean differencePPB – no PPB (95% CI).
Risk factors for bleeding after gastric ESD Libânio et altime of bleeding and tumor location, lower sites were asso-
ciated with earlier bleeding in 4 studies.29,33,34,62
Macroscopic type was also explored in several studies,
with most ﬁnding no relation between morphology and
PPB.13,18,20-24,28,29,32,34,39,42,43,61 However, ﬂat,58
depressed,16 and ﬂat/depressed14,17 lesions were associ-
ated with increased PPB in some studies.
Most studies did not ﬁnd signiﬁcant differences in PPB
according to histology (dysplasia or carci-
noma)15,18,20,22,27,28,30,34,39,42 or invasion depth (mucosal
vs submucosal),18,22-24,26-34,42,43 with few studies reporting
a signiﬁcantly increased risk of PPB in lesions harboring
carcinoma17,25 and submucosal invasion.14,36 Tumor differ-
entiation14,21,24,29,43 and lymphovascular invasion43 were
not found to inﬂuence PPB. Expanded indication lesions
were associated with higher PPB in 1 study,63 whereas
PPB was not signiﬁcantly different between standard and
expanded indications in 3 studies despite a tendency for
higher bleeding in the latter group.48,64,65
Ulceration was not associated with PPB,14,17,18,22,24,26,28-
31,33,34,37-39,43,58,65,66 except in 1 study.27 Submucosal578 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016ﬁbrosis has also been analyzed and was not identiﬁed as
an independent risk factor.13,14,61,67 The presence of scar-
ring was not identiﬁed as an inﬂuence on PPB in 3
studies,32,51,58 although it was associated with higher PPB
in 2 studies.36,59
After meta-analysis, increased tumor and specimen size,
ﬂat/depressed morphology (Fig. 4), localization in the
lesser curvature, ulceration, carcinoma histology, and
expanded indication were identiﬁed as signiﬁcant risk fac-
tors for PPB (Table 3). On the other hand, vertical localiza-
tion was not found to inﬂuence overall PPB, although
localization in the upper third was signiﬁcantly associated
with PPB in the group of studies that only reported the fre-
quency of delayed bleeding (Fig. 5). Submucosal invasion
and ﬁbrosis/scarring were not found to inﬂuence PPB
despite a tendency for higher bleeding in the latter situa-
tion. Concerning EMR, 3 studies did not identify size and
location,55 indication,64 or ulceration66 as risk factors for
PPB and were not included in the meta-analysis.
Procedural details. Poor control of bleeding18 and
snaring as the ﬁnal step of ESD68 were associated withwww.giejournal.org
TABLE 3. Lesion-related factors
Risk factor (number of studies) PPB/total (%) ORPPB* I
2
Tumor size (11) 3.04 mm (.80-5.27) 46%
>20 mm (6) 2.70 (1.44-5.06) 69%
>30 mm (1) 3.61 (1.23-10.58) N/A
>40 mm (2) 3.70 (1.10-12.45) 63%
Resection size (14) 5.29 mm (3.40-7.17) 33%
>30 mm (2) 2.85 (1.40-5.77) 43%
>40 mm (4) 2.51 (1.78-3.55) 0%
>50 mm (2) 2.99 (1.56-5.74) 59%
Vertical localization (28)
Upper (25) 101/1938 (5.2%)
Middle (25) 277/4960 (5.6%)
Lower (25) 442/7962 (5.5%)
Upper vs middle/lower (26) .99 (.72-1.37) 43%
Upper/middle vs lower (28) .99 (.80-1.21) 41%
Horizontal localization (9)
Anterior wall 38/905 (4.2%) .98 (.63-1.52) 0%
Posterior wall 49/1087 (4.5%)
Lesser curvature 91/1683 (5.4%) 1.74 (1.10-2.73) 0%
Greater curvature 30/1087 (2.8%)
Lesion morphology
Elevated (17) 212/4717 (4.5%)
Flat (9) 97/781 (12.4%)
Depressed (10) 103/1773 (5.8%)
Flat vs elevated 1.75 (1.25-2.45) 0%
Depressed vs elevated 1.24 (.84-1.82) 34%
Flat vs depressed 1.22 (.84-1.76) 0%
Flat/depressed vs elevated 1.43 (1.12-1.84) 32%
Histopathology (14)
Carcinoma 283/5513 (5.1%) 1.46 (1.12-1.91) 13%
Dysplasia 108/3052 (3.5%)
Submucosal cancer (18) 83/1619 (5.1%) 1.18 (.91-1.53) 0%
Intramucosal cancer 443/8444 (5.2%)
Ulceration (18) 73/1056 (6.9%)
390/8288 (4.7%)
1.64 (1.21-2.21) 12%
Fibrosis/scarring (6) 29/276 (10.5%)
126/2281 (5.5%)
1.87 (.96-3.62) 42%
Expanded criteria (4) 119/1419 (8.4%)
82/1931 (4.2%)
2.03 (1.24-3.33) 27%
Values in bold indicate significant risk factors.
PPB, Post-procedural bleeding; OR, odds ratio.
*Mean differencePPB – no PPB (95% CI).
Libânio et al Risk factors for bleeding after gastric ESDincreased PPB. Piecemeal resection, although not associ-
ated with higher PPB in most studies,13,14,17,20,22,34,42,61
was associated with an increased but not statistically signif-
icant risk of bleeding (Table 4).
Additional preventive measures to reduce PPB with
mucosal closure with snare and clips69 or selectivewww.giejournal.orgartery clipping70 did not decrease PPB, but coagulation
of visible vessels31,71 and use of polyglycolic acid
sheets and ﬁbrin glue72 were associated with lower
PPB rates (only in high-risk patients in the latter
study). Vascularization of lesions evaluated by EUS,73
early diet resumption,74 and outpatient managementVolume 84, No. 4 : 2016 GASTROINTESTINAL ENDOSCOPY 579
TABLE 4. Procedure-related factors
Risk factor (number
of studies) PPB/total (%) ORPPB* I
2
Piecemeal resection (9) 14/226 (6.2%)
188/4234 (4.4%)
1.78 (.89-3.55) 25%
Procedure duration
(10)
6.73 min (2.89-10.56) 4%
>60 min (3) 41/605 (6.8%)
50/1447 (3.4%)
2.05 (1.19-3.55) 25%
Preprocedural PPI (4)
Preprocedural PPI 2/208 (.96%)
4/198 (2.02%)
.70 (.14-3.53) 4%
H2RA vs PPI (6)
H2RA 44/757 (5.8%)
17/481 (3.5%)
2.13 (1.21-3.74) 0%
Experience (5)
<50 (4) 100/1786 (5.6%)
127/2534 (5.0%)
.99 (.75-1.33) 0%
<100 (3) 118/1909 (6.2%)
44/858 (5.1%)
1.12 (.77-1.63) 0%
SLE (7)
SLE 59/1349 (4.4%) 1.34 (.85-2.12) 0%
No SLE 41/1369 (2.9%)
RCT (3) 1.22 (.58-2.57) 11%
Retrospective (4) 1.45 (.79-2.65) 0%
Values in bold indicate significant risk factors.
PPB, Post-procedural bleeding; OR, odds ratio; PPI, proton pump inhibitor; H2RA,
histamine-2 receptor antagonist; SLE, second-look endoscopy; RCT, randomized
controlled trial.
*Mean differencePPB – no PPB (95% CI).
Risk factors for bleeding after gastric ESD Libânio et alin low-risk patients75 were also not found to inﬂuence
PPB.
Most studies found no signiﬁcant differences in proce-
dure duration between those with and without
PPB.16,20,21,23,24,27-31,33 However, procedure length greater
than 75 minutes,18 90 minutes,26 4 hours,36 and 5 hours76
was associated with increased PPB in some studies. In our
meta-analysis (Table 4), procedure duration was signiﬁ-
cantly higher in patients with PPB and duration > 60
minutes was signiﬁcantly associated with PPB.
Medications (PPIs, H2RAs, and mucoprotectives).
Pretreatment with PPIs before ESD was not associated
with PPB reduction11,77-79 as well as ecabet sodium added
to PPIs.62 Bolus PPI injection for 3 days yielded similar
PPB rates when compared with 72 hours’ perfusion in an
RCT.14
With regard to the direct comparison between PPIs and
H2RAs, no signiﬁcant differences in PPB were reported in 3
RCTs32,59,80 and in a retrospective study,20 whereas PPB
was signiﬁcantly lower in the PPI group in 2 studies.60,81
In our meta-analysis, H2RAs were associated with a signiﬁ-
cantly increased PPB risk.
Operator experience and fatigue. Seven studies
found no differences in PPB according to operator580 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016experience,17,18,31,36,42,61,82 with only 1 study reporting sig-
niﬁcant differences in PPB between beginner (<50 ESD)
and experienced (>200 ESD) operators.33 Meta-analysis
found that experience is not signiﬁcantly associated with
PPB (Table 4). Regarding fatigue, ESD workload > 2 hours
(but not prior other activities) was identiﬁed as a signiﬁ-
cant risk factor for early bleeding in a single study.83
Second-look endoscopy. SLE was not performed or
not reported in 30 studies, whereas SLE was routinely per-
formed after ESD in 34 studies (mostly on the ﬁrst or sec-
ond day). Seven studies directly compared PPB rates in
patients with and without SLE (3 RCTs and 4 retrospective
studies).20,22,26,30,34,61,84 The PPB rate in studies that per-
formed SLE was not signiﬁcantly different from studies
that did not perform or did not report the use of SLE.
The clinical usefulness of SLE was evaluated in 7 studies
(Table 4).20,22,26,30,34,61,84 PPB occurred in 59 of 1349
patients who underwent SLE (4.37%) and in 41 of 1369
patients who did not have SLE (2.99%), with no signiﬁ-
cant differences in the meta-analysis. Fourteen
studies13,14,17,18,20,21,23,26,28,30,34,46,61,84 reported the time
of bleeding in relation with SLE, and in these studies
53.3% of the bleeding episodes occurred before SLE. Pro-
phylactic hemostasis on SLE was associated with a signiﬁ-
cantly increased risk of PPB (compared with no
prophylactic hemostasis on SLE).DISCUSSION
This systematic review and meta-analysis evaluated risk
factors for PPB after endoscopic resection (EMR or ESD)
for gastric superﬁcial neoplasms. This is a noteworthy issue
because the literature is controversial, and many studies
are underpowered to detect small but clinically signiﬁcant
differences.
Previous meta-analysis reported procedure-related
bleeding to occur in 4% to 9% of ESDs.2-4 In our review,
bleeding after ESD occurred in 5.1% of all procedures.
We believe this is the best estimate for PPB because all
studies included were selected only if a clear deﬁnition
of PPB was provided and reported separately from intra-
procedural bleeding.
We found that male gender, cardiopathy (and AT),
cirrhosis, and chronic kidney disease were signiﬁcant clin-
ical risk factors for PPB. However, although cardiopathy
was signiﬁcantly associated with PPB, this increased risk
is most probably associated with the use of antithrom-
botics. In fact, AT was associated with an increased risk
of PPB (OR, 1.76). However, the difference in PPB rates
was not signiﬁcant in the studies that discontinued antith-
rombotics 1 week before and 1 week after ESD, suggesting
that this may be the optimal time of AT suspension when-
ever possible. Additionally, we found that continuous low-
dose aspirin was not associated with a signiﬁcant increase
in PPB in most studies.www.giejournal.org
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Figure 3. Forrest plot of PPB rate according to antithrombotic medication. Antithrombotic medication was associated with a signiﬁcantly
increased risk of PPB (pooled OR, 1.63; 95% CI, 1.30-2.03; I2 Z 1%). On subgroup analysis, antithrombotic medication was not signiﬁcantly asso-
ciated with PPB in studies that withheld antithrombotics for 1 week before and after ESD (OR, 1.23; 95% CI, .88-1.70; I2 Z 0%). PPB, post-
procedural bleeding.
Libânio et al Risk factors for bleeding after gastric ESDRegarding tumor-related characteristics, tumor size
> 20 mm, resected specimen size > 30 mm, localization
in the lesser curvature, ﬂat or depressed morphology, car-
cinoma histology, ulceration, and expanded criteria were
associated with increased PPB. On the other hand, vertical
localization was not found to affect overall PPB, but upper
lesions were in fact associated with delayed bleeding.
Procedural factors also may be associated with increased
risk of PPB, namely procedure duration > 60 minutes
and the use of H2RA as antacid medication. Operator’swww.giejournal.orgexperience was not found to inﬂuence PPB, although
high-risk lesions are typically resected by the most experi-
enced operators. Single studies found preventive coagula-
tion of visible vessels as a beneﬁcial measure in reducing
PPB, and 2 recent studies suggested that polyglycolic
acid sheets with ﬁbrin glue may reduce PPB after gastric
and colonic ESD.72,85 However, interventions like prepro-
cedural PPIs, mucoprotectives, and routine closure with
clips or artery clipping were not found to be of beneﬁt.
Endoscopic suturing of large mucosal defects after gastricVolume 84, No. 4 : 2016 GASTROINTESTINAL ENDOSCOPY 581
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Figure 4. Forrest plot of PPB rate according to lesion morphology (ﬂat/depressed vs elevated). Flat/depressed morphology was signiﬁcantly associated
with PPB in the meta-analysis (OR, 1.43; 95% CI, 1.12-1.84; I2 Z 32%). PPB, post-procedural bleeding.
Risk factors for bleeding after gastric ESD Libânio et aland colonic ESD were also reported in a single-arm study
and no adverse events were seen.86 This systematic review
may help in the selection of patients who are more likely to
beneﬁt from these developing techniques.
On the other hand, studies evaluating the beneﬁt of pre-
procedural PPI and mucoprotectives had a low event rate
and may be underpowered. Indeed, although mucoprotec-
tives were associated with faster healing of the artiﬁcial
ulcer in 2 recent reviews,87,88 its impact on PPB was not
evaluated, and so it remains unclear if these faster healing
decreases PPB.
SLE is routinely performed after ESD in several centers
to perform hemostasis in cases of active bleeding or high-
risk stigmata. Our ﬁndings clearly suggest that SLE is not
associated with decreased PPB. Furthermore, more than
one half of bleeding episodes occur before SLE, and
even prophylactic hemostasis on SLE is not capable of
reducing PPB. This suggests that even when SLE is per-
formed, special attention should be given to patients in
which prophylactic hemostasis is performed. Our ﬁndings
are consistent with a recent meta-analysis limited to RCTs
assessing SLE usefulness.89 Nevertheless, it remains un-
clear whether a subset of patients can beneﬁt. The results
were similar in retrospective studies and RCTs, although
retrospective studies could have been prone to selection
bias (eg, in 1 study the decision to perform SLE was
made at the discretion of the endoscopist,30 and in another
study the reasons to decide whether to perform SLE were
not reported34).
This systematic review and meta-analysis has some lim-
itations. First, one cannot identify interactions and con-
founding between risk factors, although we believe that
the high number of included patients and the low
heterogeneity in most evaluated risk factors allow us to582 GASTROINTESTINAL ENDOSCOPY Volume 84, No. 4 : 2016draw some important conclusions. Second, the different
temporal deﬁnitions of early and delayed bleeding made
difﬁcult a separate analysis of risk factors for early and
delayed PPB. Third, most evidence is derived from obser-
vational studies, although subgroup analysis did not ﬁnd
differences according to study design and most studies
were judged to have low risk of bias. Fourth, some risk
factors were not strictly deﬁned in some studies and
were not stratiﬁed according to disease stage (eg, Child-
Pugh classiﬁcation in cirrhosis) and so subgroup analyses
were not possible.
To our knowledge, this is the ﬁrst systematic review
about risk factors for PPB after endoscopic resection of
early gastric neoplasms and identiﬁed the most consis-
tently reported risk factors. As recommendations, we sug-
gest that (1) the deﬁnition of early and delayed bleeding
should be standardized (eg, considering early
bleeding < 24 hours after ESD) and (2) AT management
should also be reported in detail. Based on the signiﬁcant
risk factors presented on Figure 2, we also suggest that
early discharge can be considered in patients with 0 to 1
risk factors. For others, hospital stay may be prolonged
and the role of SLE adequately assessed. Randomized tri-
als should be performed incorporating these risk factors
in randomization and addressing the role for speciﬁc in-
terventions such as the use, duration, and dosage of
PPIs; SLE, and follow-up aiming at reducing the odds for
bleeding.
In conclusion, we have identiﬁed risk factors associ-
ated with PPB after ESD that can help gastroenterologists
to identify patients at increased risk. It is our hope that
this can guide management, namely in terms of the
adequate period of surveillance after endoscopic
resection.www.giejournal.org
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Figure 5. Forrest plot of PPB rate according to localization (upper vs lower). Localization of the lesion in upper or lower thirds of the stomach was
not found to inﬂuence PPB (ORupper localizationZ 1.06; 95% CI, .75-1.48; I
2Z 41%). However, in subgroup analysis upper localization was signiﬁcantly
associated with PPB when only studies reporting delayed bleeding were considered (OR, 2.55; 95% CI, 1.44-4.52; I2 Z 0%). PPB, post-procedural
bleeding.
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